Decision Resources Research Reports

Title	Published	Price
Applications of Stem Cells in Drug Discovery By: Decision Resources Stem cells are unspecialized cells that can differentiate into numerous types of specialized cells with specific functions. Diseases and disorders that might benefit from stem-cell research include Parkinson’s, Alzheimer’s, diabetes, cancer, heart disease, spinal cord \| more...	1/25/2005	$1,012.50
Cardiovascular Devices Pipeline Analysis: Innovation and Consolidation Intensify Competition By: Decision Resources The treatment of cardiovascular disease (CVD) represents a large and sustainable market growth opportunity for cardiovascular device companies. In 2003, the worldwide cardiovascular device market was estimated at $16.6 billion. High-growth opportunities within the cardiovascular \| more...	2/22/2005	$4,750.00
Spectrum Quarterly Deal Review - Fourth Quarter 2004 By: Decision Resources The life sciences industry closed 2004 with a robust fourth quarter. The industry demonstrated its vitality by attracting more than $10 billion in financing, owing mostly to a thoroughly rebounded debt financing environment. Also contributing \| more...	2/28/2005	$1,012.50
Investment and Business Trends in Biotechnology: 2004 in Review By: Decision Resources This report covers investment and business trends in Biotechnology for \| more...	3/16/2005	$1,012.50
Epidemiology-Based Market Forecasting: Pros and Cons By: Decision Resources Demand forecasting is a key activity for biopharmaceutical companies. Its many applications range from product-level volume forecasts that drive near-term manufacturing schedules and resource allocation to 10- to 20-year market forecasts that inform investment choices, \| more...	3/18/2005	$1,012.50
Advances in the Treatment of Serious Systemic Fungal Infections - An Update By: Decision Resources Opportunistic fungal infections are a major problem in immunocompromised patients. In recent years, the number of patients with severe immunosuppression has risen dramatically as a result of advances in the treatment of HIV/AIDS, cancer, and \| more...	3/18/2005	$1,012.50
Pharmaceutical Pricing, Reimbursement, and Regulatory Affairs News in the Fourth Quarter of 2004 By: Decision Resources What impact will the reelection of George W. Bush to the U.S. presidency have on the pharmaceutical industry? How is the role of generics expanding and influencing pharmaceutical industry dynamics? In this report, we review \| more...	3/21/2005	$1,012.50
Improved Diagnostic and Prognostic Tools for Rheumatoid Arthritis: Unmet Needs in a Changing Market By: Decision Resources According to recent clinical studies, the key to achieving optimal outcomes in rheumatoid arthritis (RA) is to diagnose and treat it as early as possible. The need to develop more-sensitive and more-specific markers for early-stage \| more...	3/21/2005	$1,012.50
Threats and Opportunities Facing the PSA Testing Marketplace By: Decision Resources Dramatic increases in the number of men screened for prostate cancer (CaP) and several key market drivers related to prostate-specific antigen (PSA) testing represent healthy market potential for companies active in the screening and diagnosis \| more...	4/1/2005	$1,012.50
Advances Imminent in Anti-Angiogenesis Therapeutic By: Decision Resources Angiogenesis inhibitors have interested cancer researchers since 1971, when Judah Folkman demonstrated that tumor growth depends on angiogenesis. Despite many efforts to develop angiogenesis inhibitors, however, this drug class has experienced a long and difficult \| more...	4/1/2005	$1,012.50
Antibacterial Drug Resistance: Expanding Opportunities in the Hospital Market By: Decision Resources Antibacterial resistance has always been an important driver of innovation for new antibacterial agents. Over the past 10-15 years, resistance to antibacterials in the hospital setting has risen dramatically. Although they are niche segments with \| more...	4/1/2005	$1,012.50
Pharmaceutical Innovation Through Academic Alliances By: Decision Resources For decades, pharmaceutical companies have been acutely aware of the wealth of relevant, innovative scientific research conducted outside their walls and their need to access that innovative research to boost their future success. Although these \| more...	4/1/2005	$1,012.50
Opportunities in the Pharmacotherapy of Addiction By: Decision Resources In 2003, almost 18 million people in the United States abused or were dependent on alcohol, and almost 20 million were illicit drug users. Many people abuse both alcohol and drugs. But the single most \| more...	4/5/2005	$1,012.50
The Role of Self-Medication in Cost-Containment in the United States By: Decision Resources With sales in 2003 estimated at $17.5 billion, the U.S. market for over-the-counter (OTC) drugs is by far the largest in the world, but it is arguably far from being the most dynamic self-medication market. \| more...	4/6/2005	$1,012.50
Advancing Drug Discovery Through Structure-Guided Drug Design By: Decision Resources Knowledge of protein structure is extremely valuable in drug discovery and development and extremely difficult to obtain. To date, researchers have determined 3D protein structures for only a small percentage of known genomic sequences, largely \| more...	4/19/2005	$1,012.50
Impact of Bariatric Surgeries on the Obesity Pharmaceutical Market By: Decision Resources For morbidly obese patients, bariatric surgery is an increasingly attractive option after more traditional weight loss methods have failed. The lack of long-term efficacy and the modest weight loss associated with currently marketed anti-obesity drugs—particularly \| more...	4/21/2005	$1,012.50
Integrating Diagnostics and Therapeutics for Targeted Therapies, Part 1: Optimizing the Comarketing Plan By: Decision Resources With so many targeted therapies requiring the use of a diagnostic coming to market, comarketing of diagnostics and therapeutics will become routine. This report (the first in a series of two) addresses key frameworks on \| more...	4/29/2005	$1,012.50
Outlook for Cancer Vaccine Development By: Decision Resources The incorporation of monoclonal antibodies into oncology therapy regimens has created an environment of acceptance toward new biologic therapies. Developers of cancer vaccines will be able to use this acceptance to establish these treatments as \| more...	5/23/2005	$1,012.50
Hospital Antibiotics Pipeline Analysis: Big Pharma's Retreat Creates Opportunities for Biotech By: Decision Resources Hospital Antibiotics Pipeline Analysis: Big Pharma's Retreat Creates Opportunities for Biotech Why Buy This Report? Learn what the current leading players in the HA market are doing through detailed analyses of their HA pipelines. \| more...	5/26/2005	$4,750.00
Emerging Diagnostic Markers in Alzheimer’s Disease By: Decision Resources Currently, Alzheimer’s disease (AD) is diagnosed based on patient clinical history and exclusion of other neurological disorders. Because early signs of AD are hard to distinguish from normal signs of aging, most patients are not \| more...	6/14/2005	$1,012.50
The Vioxx Withdrawal: Changes and Opportunities for the Industry By: Decision Resources The safety issues that precipitated the withdrawal of Vioxx from the U.S. market have had a devastating effect on the market potential of the selective COX-2 inhibitor class and raised doubts about the safety of \| more...	6/14/2005	$1,012.50
Knowledge Management Tools for Drug Discovery By: Decision Resources Pharmaceutical companies are investing in new R&D technologies in the hope that they will accelerate research and, ultimately, improve both productivity and profitability. Before these technologies can boost profitability, however, the data they produce must \| more...	6/15/2005	$1,012.50
Obesity Drug Discovery: Success and Challenges for a New Pharmaceutical Market By: Decision Resources In recent years, obesity has become a major health problem for many postindustrial societies, so much so that in 2004, the United States Health and Human Services declared obesity to be a disease. Obesity poses \| more...	6/15/2005	$1,012.50
Novel Strategies in Oncology Clinical Trials: The Use of Biological and Imaging Biomarkers By: Decision Resources Biomarkers have the potential to play a valuable role in simplifying the pharmaceutical development process. They can be used to identify patient populations, improve dosing regimens, and alter delivery routes to adjust responses. This report \| more...	6/16/2005	$1,012.50
Overview of the Bulgarian and Romanian Pharmaceutical Markets By: Decision Resources In 2007, Bulgaria and Romania are scheduled to join 25 other countries as member states of the European Union (EU). Before doing so, however, Bulgaria and Romania must implement wide-ranging political, economic, and legal reforms, \| more...	6/20/2005	$1,012.50
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/24/2009 - 3